Concepedia

Labile iron in parenteral iron formulations: a quantitative and comparative study

David Van Wyck, Jaime Anderson, Kevin Johnson

Nephrology Dialysis Transplantation · 2004 · 99 citations · 17 references

DOIFull text

Open access

Abstract

Approximately 2-6% of total iron in commonly used IV iron compounds is available for in vitro iron donation to Tf. This fraction may contribute to evidence of bioactive iron in patients after IV iron administration.

References

17

EPIBACDIAL

Bruno Hoen, A. Paul-Dauphin, D. Hestin et al. · Journal of the American Society of Nephrology · 1998 · 514 citations

, , +13

A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients

Hans Furuland · Nephrology Dialysis Transplantation · 2003 · 226 citations · Full text

Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury

Richard A. Zager, Ali C.M. Johnson, Sherry Y. Hanson et al. · American Journal of Kidney Diseases · 2002 · 209 citations

, , +10

Iron Administration and Clinical Outcomes in Hemodialysis Patients

Harold I. Feldman, Jill Santanna, Wensheng Guo et al. · Journal of the American Society of Nephrology · 2002 · 145 citations

Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron–saccharate administration

J Parkkinen, Leni von Bonsdorff, Carola Grönhagen‐Riska et al. · Nephrology Dialysis Transplantation · 2000 · 135 citations